# US 2006/0188493 A1 · Use of an active substance that binds to cd28 for producing a pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0188493 A1
- Document ID: US20060188493A1
- Status: Published application
- Kind: A1
- Application number: 10/507,798
- Filed: 2003-03-13
- Published: 2006-08-24
- Earliest claimed: 2002-03-13
- Assignees: Tegenero AG
- Inventors: Huenig Thomas
- Web page: https://patentgrep.com/patent/US20060188493A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61P 37/02: Immunomodulators
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimic compound of the same for producing a pharmaceutical composition for the induction and/or reproduction of regulatory T-cells.

## Claims

### Claim 1

The use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimic compound of the same for producing a pharmaceutical composition for the induction and/or reproduction of regulatory T-cells in vitro and/or in vivo.

### Claim 2 (depends on 1)

The use in particular according to claim 1 for the treatment and/or prophylaxis of autoimmune diseases and/or inflammatory reactions.

### Claim 3 (depends on 1)

The use in particular according to claim 1 for the treatment of the Guillain-Barré syndrome (GBS) or of the chronic demyelinating polyneuropathy (CDP).

### Claim 4 (depends on 1, 2, 3)

The use according to one of claims 1 to 3, wherein the mAb can be produced by that a non-human mammal is immunized with CD28 or a partial sequence herefrom, in particular the C′-D loop, cells being taken from the non-human mammal and hybridoma cells being produced from the cells, and the thus obtained hybridoma cells being selected such that in their culture supernatant there are mAbs that superagonistically bind to CD28.

### Claim 5 (depends on 1, 2, 3, 4)

The use according to one of claims 1 to 4, wherein the mimic compound is obtainable in a screening method, a prospective mimic compound or a mixture of prospective mimic compounds being subjected to a binding assay with CD28 or a partial sequence herefrom, in particular the C′-D loop, and active substances binding to CD28 or to the partial sequence herefrom being selected, possibly followed by an assay for testing for superagonistic stimulation of several to all sub-groups of the T lymphocytes.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The use according to one of claims 1 to 5, wherein the mAb is obtainable from hybridoma cells, as filed under the DSM numbers DSM ACC2531 (mAb: 9D7 or 9D7G3H11) or DSM ACC2530 (mAb: 5.11A or 5.11A1C2H3).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The use according to one of claims 1 to 6, wherein the mAb or the mimic compound comprises one or more of the sequences Seq. ID 9, 11, 13 and/or 15, or one or more sequences Seq. ID 10, 12, 14 and/or 16, or one or more of the sequences 18 and/or 19, or sequences being homologous hereto.

### Claim 8 (depends on 2, 3)

A method for the treatment or prophylaxis of a disease according to claim 2 or 3, wherein either
to a patient is administered a pharmaceutical composition comprising a CD28-specific superagonistic monoclonal antibody or a mimic compound of the same and in a galenic preparation for a defined and suitable form of administration, for instance IV injection, or
from a patient is taken a body liquid, in particular blood comprising T lymphocytes or precursor cells hereto, and the body liquid, possibly after a processing step, is reacted with a CD28-specific superagonistic monoclonal antibody or a mimic compound of the same, and the thus treated body liquid is again administered to the patient, for instance by IV injection.
